Fig. 4. Translocation of PKC ε to cardiomyocytes. (A ) Percentages of protein kinase C (PKC) ε–positive myocytes. Data are mean ± SD. (B ) Representative nucleus of a PKC ε–positive cardiomyocyte. (C ) Cardiomyocyte with no PKC ε but lipofuscin pigment in the nucleus. (D ) Cardiomyocyte with neither PKC ε nor pigment in the nucleus. *Significantly increased compared with pre-SEVO (before sevoflurane preconditioning) (P < 0.001). †Not significantly different from pre-SEVO or pre-PLACEBO (before placebo preconditioning). Post-PLACEBO = time-matched control after placebo preconditioning; post-SEVO = after sevoflurane preconditioning.